The cardiac biomarkers market will generate a value of USD 20,718.8 million by 2030, powering at a compound annual growth rate of 10.5% by the end of this decade. This is because of the growing incidence of ACS, tech progressions in cardiac biomarkers, increasing demand for point-of-care testing kits, and requirement for high specificity in the recognition of cardiac disorders, chiefly myocardial infarction.
Troponin had the major revenue share of, more than 35%, in the recent past, and this wil
